Complement C1s Overview
Molecule Name
Complement C1s
Synonyms
EDSPD2
Drug Development Progress
Drugs in Clinical Trials5
Approved Drugs4
Highest Development StageApproved
Target Synonym
EC:3.4.21.42，EC 3.4.21，C1 esterase，Complement component 1 subcomponent s，C1S，Complement C1s，Complement Component 1， S Subcomponent，Basic Proline-Rich Peptide IB-1，Complement C1s Subcomponent，EC 3.4.21.42，EDSPD2
Background
This gene encodes a serine protease, which is a major constituent of the human complement subcomponent C1. C1s associates with two other complement components C1r and C1q in order to yield the first component of the serum complement system. Defects in this gene are the cause of selective C1s deficiency.
Complement C1s Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Complement-C1 inhibitor protein (Octapharma) | Phase 3 Clinical | Octapharma | Angioedemas, Hereditary | Details | |
| Riliprubart | BIVV-020; SAR-445088; TNT-020 | Phase 3 Clinical | True North Therapeutics | Anemia, Hemolytic, Autoimmune; Graft Rejection; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic | Details |
| C1 esterase inhibitor (Boya Bio-Pharmaceutical) | Phase 3 Clinical | Boya Bio-Pharmaceutical Group Co Ltd | Angioedemas, Hereditary | Details | |
| Claseprubart | DNTH103; DNTH-103 | Phase 3 Clinical | Dianthus Therapeutics Inc | Autoimmune Diseases; Motor Neuron Disease; Multifocal Motor Neuropathy; Myasthenia Gravis; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Details |
| C1 esterase inhibitor (Chengdu Institute of Biological Products) | Phase 1 Clinical | Chengdu Institute Of Biological Products Co Ltd | Angioedemas, Hereditary | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Conestat alfa | rhC1-INH | Approved | Pharming Group Nv | Rhucin, Esterasine, Ruconest | EU | Angioedemas, Hereditary | Pharming Group Nv | 2010-10-28 | Angioedema; Angioedemas, Hereditary; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Fatigue Syndrome, Chronic; Genetic Diseases, Inborn; Graft Rejection; Non-ST Elevated Myocardial Infarction; Rejection of renal transplantation; Renal Insufficiency | Details |
| Sutimlimab | BIVV-009; TNT-009 | Approved | True North Therapeutics | ENJAYMO | United States | Anemia, Hemolytic, Autoimmune | Recordati Rare Diseases Inc | 2022-02-04 | Anemia, Hemolytic, Autoimmune; Clostridium Infections; Hemolysis; Kidney Failure, Chronic; Pemphigoid, Bullous; Purpura, Thrombocytopenic, Idiopathic | Details |
| Complement C1 inhibitor protein (Shire ViroPharma) | C1 INH-nf; C1-INH; SHP-616 | Approved | Sanquin Plasma Products Bv | Cinryze, Cetor | United States | Angioedemas, Hereditary | null | 2008-10-10 | Angioedemas, Hereditary; Brain Injuries, Traumatic; Graft Rejection; Rejection of organ transplantation | Details |
| C1 esterase inhibitor (Human, CSL Behring) | BI-3.012; CSL-830; CSL-842; CE-1145 | Approved | Csl Behring Llc | Berinert, Haegarda, Berinert 2000 | Japan | Angioedemas, Hereditary | Csl Behring Llc | 1990-06-29 | Angioedemas, Hereditary; Hereditary Angioedema Types I and II; Rejection of renal transplantation | Details |